Amylyx Pharmaceuticals Inc

Research Amylyx Pharmaceuticals Inc (AMLX) on Bullrun: market cap USD 2.08B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAMLX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryDrug Manufacturers-Specialty & Generic
• CurrencyUSD
• Market capUSD 2.08B
• Financial periodFY2025
• Revenue growth-100.0%
• Net income-USD 144.74M
• Free cash flow-USD 123.48M

Valuation Snapshot

latest market cap is USD 2.08B.

About Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.

Frequently asked questions

What is Amylyx Pharmaceuticals Inc's market cap?

Amylyx Pharmaceuticals Inc's market capitalization is USD 2.08B.

What does Amylyx Pharmaceuticals Inc do?

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.